Increase in level of tumor necrosis factor-α in 6-hydroxydopamine-lesioned striatum in rats is suppressed by immunosuppressant FK506

• Published in: Neuroscience letters Vol. 289; no. 3; pp. 165 - 168
• Main Authors: Mogi, Makio, Togari, Akifumi, Tanaka, Ken-ichi, Ogawa, Norio, Ichinose, Hiroshi, Nagatsu, Toshiharu
• Format: Journal Article
• Language: English
• Published: Shannon Elsevier Ireland Ltd 11.08.2000; Elsevier
• Subjects: 6-Hydroxydopamine; Animals; Biological and medical sciences; Brain; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Dopamine - metabolism; FK506; Functional Laterality - drug effects; Functional Laterality - physiology; Immunosuppressive Agents - pharmacology; Male; Medical sciences; Neostriatum - drug effects; Neostriatum - immunology; Neostriatum - physiopathology; Neural Pathways - drug effects; Neural Pathways - immunology; Neural Pathways - physiopathology; Neurology; Neurons - drug effects; Neurons - metabolism; Neurons - pathology; Neuroprotective Agents - pharmacology; Oxidopamine - adverse effects; Parkinson's disease; Parkinsonian Disorders - chemically induced; Parkinsonian Disorders - drug therapy; Parkinsonian Disorders - immunology; Parkinsonian Disorders - physiopathology; Rat; Rats; Rats, Sprague-Dawley; Substantia Nigra - drug effects; Substantia Nigra - immunology; Substantia Nigra - physiopathology; Tacrolimus - pharmacology; Tumor Necrosis Factor-alpha - drug effects; Tumor Necrosis Factor-alpha - metabolism; Tumor necrosis factor-α; Brain; Parkinson's disease; FK506; Tumor necrosis factor-α; Rat; 6-Hydroxydopamine; Nervous system diseases; Rodentia; Central nervous system; Parkinson disease; Basal ganglion; Corpus striatum; Oxidopamine; Cerebral disorder; Vertebrata; Experimental disease; Mammalia; Animal; Central nervous system disease; Degenerative disease; Immunosuppressive agent; Lesion; Tumor necrosis factor α; Brain (vertebrata); Extrapyramidal syndrome
• ISSN: 0304-3940; 1872-7972
• DOI: 10.1016/S0304-3940(00)01275-1

We compared in rats with 6-hydroxydopamine (6-OHDA)-induced hemiparkinsonism the content of tumor necrosis factor (TNF)-α in the nigrostriatal dopaminergic region of the control side with that of the 6-OHDA-injected experimental side, and explored the effects of 6-OHDA injection combined with the immunosuppressant FK506 treatment (0.5 or 4 mg/kg per day for 2 weeks). The ratios of the concentration of TNF-α in the striatum and substantia nigra on the 6-OHDA injection side to that on the control side in the 6-OHDA hemiparkinsonism rats were significantly higher than those in the control rats without 6-OHDA treatment, whereas those in the rats treated with 6-OHDA and FK506 were not significantly different from those in the control rats. Thus FK506 attenuated increased TNF-α level in the nigrostriatal dopaminergic region injured by 6-OHDA treatment.